The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | CAPRI-2 GOIM: ctDNA-guided cetuximab sequencing in colorectal cancer
Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, xplores results from the CAPRI-2 GOIM trial (NCT05312398), evaluating plasma circulating tumor DNA comprehensive genomic profiling to guide sequential cetuximab-based therapy in RAS/BRAF wild-type, microsatellite stable metastatic colorectal cancer. Patients without resistance-associated variants (“negative hyperselected”) had significantly better response rates and progression-free survival with continued cetuximab across first- and second-line treatment compared with those harboring resistance variants. Findings support using liquid biopsy profiling to identify patients likely to benefit from ongoing anti-epidermal growth factor receptor therapy. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
